Key result
Low-dose alteplase achieves complete pacemaker lead thrombus resolution in a hemodynamically stable patient.
Why the study?
Pacemaker lead-associated thrombosis is a clinically significant condition leading to embolic complications and hemodynamic instability, but its treatment is not protocolized.
Does low-dose systemic alteplase infusion resolve pacemaker lead thrombus and pulmonary embolism in a hemodynamically stable patient with high clot burden?
Case Report (n=1)
Does low-dose systemic alteplase infusion resolve pacemaker lead thrombus and pulmonary embolism in a hemodynamically stable patient with high clot burden?
Low-dose systemic alteplase infusion successfully and safely resolved a large pacemaker lead thrombus and pulmonary embolism in a hemodynamically stable elderly patient.
May prompt consideration of lead thrombosis in pacemaker patients with acute dyspnea; leaves open optimal management strategies.
Pacemaker lead-associated thrombosis is a rare but clinically significant condition that can lead to embolic complications and hemodynamic instability. Management of pacemaker lead-associated thrombi can range from anticoagulation or systemic thrombolysis to catheter-based extraction and surgical removal. In this case, an 80-year-old male patient presented to the Emergency Department (ED) with acute exertional dyspnea and was found to have extensive left lower extremity deep vein thrombosis (DVT), bilateral segmental pulmonary embolism (PE), and a thrombus adhered to the right atrial pacemaker lead. He was treated with low-dose intravenous alteplase infusion as well as heparin in the intensive care unit, leading to rapid thrombus resolution. He was subsequently transitioned to a direct-acting oral anticoagulant (DOAC) and discharged in stable condition. Treatment for pacemaker lead thrombi is not protocolized, given the dependence on various patient-related and situational factors. This case highlights the importance of early recognition and management of pacemaker lead-associated thrombosis and demonstrates a novel treatment approach in the form of low-dose alteplase infusion. Low-dose thrombolytics may be a safer and less invasive treatment modality in hemodynamically stable patients with a high clot burden.
No takes yet. Share an insight, caveat, or question.
Pilkington et al. (2026) conducted a case report in Pulmonary embolism, deep vein thrombosis, and pacemaker lead thrombus (n=1). Low-dose systemic thrombolytic infusion (alteplase) was evaluated on Thrombus resolution. Low-dose intravenous alteplase infusion (1 mg/hr for 12 hours) led to rapid and complete resolution of a pacemaker lead thrombus in a hemodynamically stable patient with extensive clot burden.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: